Last reviewed · How we verify
NCT03133871
Evaluation of Scanoskin for the Assessment of Vitiligo
trial in Vitiligo in 15 participants. Completed in 20 November 2018.
20 November 2018
Quick facts
| Lead sponsor | Chelsea and Westminster NHS Foundation Trust |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 15 |
| Start date | 1 March 2017 |
| Primary completion | 20 November 2018 |
| Estimated completion | 20 November 2018 |
| Sites | 1 location across United Kingdom |
Conditions studied
- Vitiligo — all drugs for Vitiligo →
Sponsor
Chelsea and Westminster NHS Foundation Trust
Who can join
Adults 18 to 100, any sex, with Vitiligo. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to establish whether the use of a special digital camera (SIAscopy) can provide an accurate and reliable measure of vitiligo which is at least equivalent to the current gold standard of planimetry. If so, SIAscopy could be used as an objective diagnostic and prognostic tool in the management of vitiligo patients within dermatology departments and allow a fair and accurate assessment of new potential treatments.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Skin immunity and its dysregulation in atopic dermatitis, hidradenitis suppurativa and vitiligo.
Campione E, Lanna C, Diluvio L, Cannizzaro MV, et al · · 2020 · cited 32× · PMID 31905036 · DOI 10.1080/15384101.2019.1707455
Verify or expand the search:
- PubMed search for NCT03133871
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Vitiligo
Currently open trials in the same condition.
- NCT07153666 — A Real-world Study on the Influencing Factors of Efficacy of Ruxolitinib Cream in Vitiligo · recruiting
- NCT07267273 — Betamethasone Phonophoresis For Vitiligo · NA · recruiting
- NCT07232238 — TRPM2 Gene Polymorphism, NLRP3 Inflammasome Expression in Vitiligo Patients · active not recruiting
- NCT07532330 — Tyrosine Vs Tacrolimus With NB-UVB in Vitiligo · NA · active not recruiting
- NCT07357870 — A Proof of Concept, Phase 1 Study of CGB-600 for the Topical Treatment of Non-Segmented Facial Vitiligo · Phase 1 · recruiting
Other Chelsea and Westminster NHS Foundation Trust trials
Trials by the same sponsor.
- NCT07124390 — Electroacupuncture as a Treatment for Refractory Overactive Bladder · NA · not yet recruiting
- NCT07202221 — Spoken Animation for Labour Epidural · NA · not yet recruiting
- NCT06775769 — Endometrioma Sclerotherapy and Ovarian Preservation · NA · recruiting
- NCT05289986 — The Effect on Lipid Profile of Switching to Delstrigo in HIV Positive Patients · Phase 4 · terminated
- NCT06118632 — Physiological and Environmental Data in a Remote Setting to Predict Exacerbation Events in Patients With Chronic Obstruc · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03133871 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chelsea and Westminster NHS Foundation Trust
- Last refreshed: 30 September 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03133871.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing